Rutherford Health - Acquisition Update
RNS Number : 0223Q
Rutherford Health PLC
25 October 2021
 

Rutherford Health Plc

("Rutherford" or "the Company")

25 October 2021

 

Further to its announcements of 31 August 2021 and 22 September 2021, the Company announces that the date by which the conditions to complete the acquisition of all the shares in Proton Partners International Health Care Investments LLC, UAE have to be satisfied or waived has been extended to the date 80 days after the date of the date of the Share Swap Deed, being to 16 November 2021. 

 

-Ends-

For more information, please contact:

 

Rutherford Health plc

+44 (0) 16 3381 0661

Michael Moran, Chief Executive Officer
Marcus King, Finance Director

Investors@therutherford.com



Grant Thornton (Corporate Adviser)

+44 (0) 20 7383 5100

Colin Aaronson / George Grainger




Instinctif Partners

+44 207 457 2020

Melanie Toyne-Sewell / Jeremy Durrant / Rozi Morris
 

Rutherford@Instinctif.com



Media House International

07788 414 856 / 0207 710 0020

Ramsay Smith

ramsay@mediahouse.co.uk

 

 

About Rutherford Health plc

Rutherford Health plc is a leading UK provider of innovative cancer care. Operating a network of four state-of-the-art centres in Wales, Reading, Northumberland and Liverpool, Rutherford Health offers a comprehensive range of the latest technology in cancer treatments, and is the only independent provider of proton beam therapy ("PBT") in the UK. The Company also provides conventional radiotherapy, chemotherapy, immunotherapy, imaging and wellbeing services.

The Company is listed on the Apex segment of the AQSE Growth Market under the symbol: RUTH. For more information, visit the Group's website: www.rutherfordhealth.com .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXVXLBLFBLZFBB ]]>